Astellas To Market Pain Patch Of NeurogesX Of U.S.
This article was originally published in PharmAsia News
Astellas Pharma has agreed to market U.S.-based NeurogesX's patch for relieving pain in Europe, Africa and the Middle East. The drug is Qutenza (capsaicin), which has European Union approval, but is not yet approved in the United States. Under the agreement, Astellas is to pay NeurogesX $42 million upfront for marketing rights. The drug patch is expected to be launched in the first half of next year. (Click here for more
You may also be interested in...
Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.
US pharmacy group says that 10 to 12 states have indicated through an informal survey that they do not have the manpower or funding to implement the US FDA’s final MOU on inordinate compounding. They say what is at stake in these states is patient access to compounded medicines.
Mayo Clinic announces AI-based partnerships with Google and voice-analysis company Vocalis Health this week.